Upregulation of microRNA-370 promotes cell apoptosis and inhibits proliferation by targeting PTEN in human gastric cancer

Zeng,Yang; Fu,Meng; Wu,Gang-Wei; Zhang,An-Zu; Chen,Jin-Ping; Lin,Hong-Yue; Fu,Yong-An; Jia,Jing; Cai,Zong-Da; Wu,Xiao-Jian; Lan,Ping

doi:10.3892/ijo.2016.3642

Upregulation of microRNA-370 promotes cell apoptosis and inhibits proliferation by targeting PTEN in human gastric cancer

Authors:
- Yang Zeng
- Meng Fu
- Gang-Wei Wu
- An-Zu Zhang
- Jin-Ping Chen
- Hong-Yue Lin
- Yong-An Fu
- Jing Jia
- Zong-Da Cai
- Xiao-Jian Wu
- Ping Lan
View Affiliations

Affiliations: Department of General Surgery, The First Affiliated Quanzhou Hospital of Fujian Medical University, Quanzhou, Fujian 362000, P.R. China, Department of Colorectal and Anal Surgery, The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong 510000, P.R. China
Published online on: August 2, 2016 https://doi.org/10.3892/ijo.2016.3642
Pages: 1589-1599

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Growing evidence suggests that microRNA plays an essential role in the development and metastasis of many tumors, including gastric cancer. Aberrant miR‑370 expression has been indicated in tumor growth, but the mechanism of miR‑370 inhibits both the proliferation and metastatic ability for gastric cancer remains unclear. Accumulating evidence reported that PTEN signaling pathway plays an important role in the cellular processes, such as apoptosis, cell growth and proliferation. The goal of this study was to identify whether miR‑370 could inhibit the growth, migration, invasion, proliferation and metastasis of gastric cancer through targeting PTEN. Real-time PCR (RT-PCR) was used to quantify miR-370 expression in vitro experiments. The biological functions of miR‑370 were determined via cell proliferation. Our study indicated that miR‑370 targeted PTEN leading to activation of apoptosis signaling and the cell proliferation of cervical cancer cells, ameliorating gastric cancer growth and progression. In addition, the combination of miR‑370 and PTEN inactivated AKT, MDM2 and mTOR while stimulated caspase-3, p53 and GSK3β expression, promoting apoptosis and suppressing proliferation of gastric cancer cells. Therefore, our study revealed the mechanistic links between miR‑370 and PTEN in the pathogenesis of gastric cancer through modulation of cell apoptosis and proliferation. Additionally, targeting miR‑370 could serve as a novel strategy for future gastric cancer therapy clinically.

View Figures

View References

1	Karpińska-Kaczmarczyk K, Lewandowska M, Białek A, Ławniczak M and Urasińska E: Gastric hyperplastic polyps coexisting with early gastric cancers, adenoma and neuroendocrine cell hyperplasia. Pol J Pathol. 67:33–38. 2016. View Article : Google Scholar
2	Jung Y, Park J, Bang YJ and Kim TY: Gene silencing of TSPYL5 mediated by aberrant promoter methylation in gastric cancers. Lab Invest. 88:153–160. 2008. View Article : Google Scholar
3	Ushijima T and Sasako M: Focus on gastric cancer. Cancer Cell. 5:121–125. 2004. View Article : Google Scholar : PubMed/NCBI
4	Smith MG, Hold GL, Tahara E and El-Omar EM: Cellular and molecular aspects of gastric cancer. World J Gastroenterol. 12:2979–2990. 2006. View Article : Google Scholar : PubMed/NCBI
5	Panani AD: Cytogenetic and molecular aspects of gastric cancer: Clinical implications. Cancer Lett. 266:99–115. 2008. View Article : Google Scholar : PubMed/NCBI
6	Maxwell AW, Wood S and Dupuy DE: Primary extraskeletal Ewing sarcoma of the stomach: A rare disease in an uncommon location. Clin Imaging. 40:843–845. 2016. View Article : Google Scholar : PubMed/NCBI
7	Iorio MV and Croce CM: MicroRNAs in cancer: Small molecules with a huge impact. J Clin Oncol. 27:5848–5856. 2009. View Article : Google Scholar : PubMed/NCBI
8	Hobert O: Gene regulation by transcription factors and microRNAs. Science. 319:1785–1786. 2008. View Article : Google Scholar : PubMed/NCBI
9	Glud M, Rossing M, Hother C, Holst L, Hastrup N, Nielsen FC, Gniadecki R and Drzewiecki KT: Downregulation of miR-125b in metastatic cutaneous malignant melanoma. Melanoma Res. 20:479–484. 2010. View Article : Google Scholar : PubMed/NCBI
10	Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W, et al: Relation between microRNA expression and progression and prognosis of gastric cancer: A microRNA expression analysis. Lancet Oncol. 11:136–146. 2010. View Article : Google Scholar
11	Croce C: Introduction to the role of microRNAs in cancer diagnosis, prognosis, and treatment. Cancer J. 18:213–214. 2012. View Article : Google Scholar : PubMed/NCBI
12	Nikitina EG, Urazova LN and Stegny VN: MicroRNAs and human cancer. Exp Oncol. 34:2–8. 2012.PubMed/NCBI
13	Holley CL and Topkara VK: An introduction to small non-coding RNAs: miRNA and snoRNA. Cardiovasc Drugs Ther. 25:151–159. 2011. View Article : Google Scholar : PubMed/NCBI
14	Baroni D and Arrigo P: MicroRNA target and gene validation in viruses and bacteria. Methods Mol Biol. 1107:223–231. 2014. View Article : Google Scholar
15	Sim J, Ahn H, Abdul R, Kim H, Yi KJ, Chung YM, Chung MS, Paik SS, Song YS and Jang K: High MicroRNA-370 expression correlates with tumor progression and poor prognosis in breast cancer. J Breast Cancer. 18:323–328. 2015. View Article : Google Scholar
16	Duan N, Hu X, Yang X, Cheng H and Zhang W: MicroRNA-370 directly targets FOXM1 to inhibit cell growth and metastasis in osteosarcoma cells. Int J Clin Exp Pathol. 8:10250–10260. 2015.PubMed/NCBI
17	Chen T, Gao F, Feng S, Yang T and Chen M: MicroRNA-370 inhibits the progression of non-small cell lung cancer by down-regulating oncogene TRAF4. Oncol Rep. 34:461–468. 2015.PubMed/NCBI
18	Cantley LC and Neel BG: New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA. 96:4240–4245. 1999. View Article : Google Scholar : PubMed/NCBI
19	Yo YT, Shieh GS, Hsu KF, Wu CL and Shiau AL: Licorice and licochalcone-A induce autophagy in LNCaP prostate cancer cells by suppression of Bcl-2 expression and the mTOR pathway. J Agric Food Chem. 57:8266–8273. 2009. View Article : Google Scholar : PubMed/NCBI
20	Lev Bar-Or R, Maya R, Segel LA, Alon U, Levine AJ and Oren M: Generation of oscillations by the p53-Mdm2 feedback loop: A theoretical and experimental study. Proc Natl Acad Sci USA. 97:11250–11255. 2000. View Article : Google Scholar : PubMed/NCBI
21	Yoshikawa T, Aoyama T, Tanabe K, Nishikawa K, Ito Y, Hayashi T, Cho H, Miyashita Y, Tsuburaya A and Sakamoto J: Feasibility and safety of transhiatal approach and D2 total gastrectomy after neoadjuvant chemotherapy for adenocarcinoma of the esophago-gastric junction: A subset analysis of the COMPASS trial. Dig Surg. 33:424–430. 2016. View Article : Google Scholar : PubMed/NCBI
22	Burkitt MD, Varro A and Pritchard DM: Importance of gastrin in the pathogenesis and treatment of gastric tumors. World J Gastroenterol. 15:1–16. 2009. View Article : Google Scholar :
23	Kozomara A and Griffiths-Jones S: miRBase: Integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res. 39(Database): D152–D157. 2011. View Article : Google Scholar :
24	Wojcicka A, Swierniak M, Kornasiewicz OW, Maciag M, Kolanowska M, Kotlarek M, Gornicka B, Koperski L, Niewinski G, et al: Next generation sequencing reveals microRNA isoforms in liver cirrhosis and hepatocellular carcinoma. Int J Biochem Cell Biol. 53:208–217. 2014. View Article : Google Scholar : PubMed/NCBI
25	Nielsen CB, Shomron N, Sandberg R, Hornstein E, Kitzman J and Burge CB: Determinants of targeting by endogenous and exogenous microRNAs and siRNAs. RNA. 13:1894–1910. 2007. View Article : Google Scholar : PubMed/NCBI
26	Jazdzewski K, Boguslawska J, Jendrzejewski J, Liyanarachchi S, Pachucki J, Wardyn KA, Nauman A and de la Chapelle A: Thyroid hormone receptor beta (THRB) is a major target gene for microRNAs deregulated in papillary thyroid carcinoma (PTC). J Clin Endocrinol Metab. 96:E546–E553. 2011. View Article : Google Scholar
27	Courtney KD, Corcoran RB and Engelman JA: The PI3K pathway as drug target in human cancer. J Clin Oncol. 28:1075–1083. 2010. View Article : Google Scholar : PubMed/NCBI
28	Song MS, Salmena L and Pandolfi PP: The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 13:283–296. 2012.PubMed/NCBI
29	Downes CP, Perera N, Ross S and Leslie NR: Substrate specificity and acute regulation of the tumour suppressor phosphatase, PTEN. Biochem Soc Symp. 74:69–80. 2007. View Article : Google Scholar : PubMed/NCBI
30	Kong D and Yamori T: Advances in development of phosphatidylinositol 3-kinase inhibitors. Curr Med Chem. 16:2839–2854. 2009. View Article : Google Scholar : PubMed/NCBI
31	Roy S, Yu Y, Padhye SB, Sarkar FH and Majumdar AP: Difluorinated-curcumin (CDF) restores PTEN expression in colon cancer cells by down-regulating miR-21. PLoS One. 8:e685432013. View Article : Google Scholar : PubMed/NCBI
32	Kunze D, Wuttig D, Fuessel S, Kraemer K, Kotzsch M, Meye A, Grimm MO, Hakenberg OW and Wirth MP: Multitarget siRNA inhibition of antiapoptotic genes (XIAP, BCL2, BCL-X(L)) in bladder cancer cells. Anticancer Res. 28B:2259–2263. 2008.
33	Wang YB, Qin J, Zheng XY, Bai Y, Yang K and Xie LP: Diallyl trisulfide induces Bcl-2 and caspase-3-dependent apoptosis via downregulation of Akt phosphorylation in human T24 bladder cancer cells. Phytomedicine. 17:363–368. 2010. View Article : Google Scholar
34	Bouska A, Lushnikova T, Plaza S and Eischen CM: Mdm2 promotes genetic instability and transformation independent of p53. Mol Cell Biol. 28:4862–4874. 2008. View Article : Google Scholar : PubMed/NCBI
35	Clegg HV, Itahana K and Zhang Y: Unlocking the Mdm2-p53 loop: Ubiquitin is the key. Cell Cycle. 7:287–292. 2008. View Article : Google Scholar : PubMed/NCBI
36	Yamashita SI, Masuda Y, Yoshida N, Matsuzaki H, Kurizaki T, Haga Y, Ikei S, Miyawaki M, Kawano Y, Chujyo M, et al: p53AIP1 expression can be a prognostic marker in non-small cell lung cancer. Clin Oncol (R Coll Radiol). 20:148–151. 2008. View Article : Google Scholar
37	Iwakuma T and Lozano G: MDM2, an introduction. Mol Cancer Res. 1:993–1000. 2003.
38	Günther T, Schneider-Stock R, Häckel C, Kasper HU, Pross M, Hackelsberger A, Lippert H and Roessner A: Mdm2 gene amplification in gastric cancer correlation with expression of Mdm2 protein and p53 alterations. Mod Pathol. 13:621–626. 2000. View Article : Google Scholar : PubMed/NCBI
39	Granville CA, Memmott RM, Gills JJ and Dennis PA: Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin Cancer Res. 12:679–689. 2006. View Article : Google Scholar : PubMed/NCBI
40	Markman B, Atzori F, Pérez-García J, Tabernero J and Baselga J: Status of PI3K inhibition and biomarker development in cancer therapeutics. Ann Oncol. 21:683–691. 2010. View Article : Google Scholar
41	Karar J and Maity A: PI3K/AKT/mTOR pathway in angiogenesis. Front Mol Neurosci. 4:512011. View Article : Google Scholar : PubMed/NCBI